Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:TCRR

TCR2 Therapeutics (TCRR) Stock Price, News & Analysis

TCR2 Therapeutics logo

About TCR2 Therapeutics Stock (NASDAQ:TCRR)

Key Stats

Today's Range
$1.48
$1.48
50-Day Range
$1.48
$1.98
52-Week Range
$0.82
$3.88
Volume
N/A
Average Volume
494,777 shs
Market Capitalization
$58.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive TCRR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TCRR Stock News Headlines

Poseida Therapeutics Inc Ordinary Shares PSTX
DICE Therapeutics Inc.
Why More Investors Are Using Family Trusts to Protect Their Wealth
For many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.tc pixel
TCR2 Therapeutics Insider Trades Send a Signal
Recap: TCR2 Therapeutics Q1 Earnings
10-Q: TCR2 THERAPEUTICS INC.
See More Headlines

TCRR Stock Analysis - Frequently Asked Questions

TCR2 Therapeutics Inc. (NASDAQ:TCRR) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.63) by $0.06.

TCR2 Therapeutics (TCRR) raised $76 million in an initial public offering (IPO) on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that TCR2 Therapeutics investors own include Digital Turbine (APPS), CrowdStrike (CRWD), Okta (OKTA), Vuzix (VUZI) and SoFi Technologies (SOFI).

Company Calendar

Last Earnings
11/10/2021
Today
9/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TCRR
CIK
1750019
Fax
N/A
Employees
137
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($4.20)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$151.82 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-97.81%
Return on Assets
-69.35%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.96
Quick Ratio
2.96

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.58 per share
Price / Book
0.57

Miscellaneous

Outstanding Shares
39,260,000
Free Float
29,443,000
Market Cap
$58.10 million
Optionable
Not Optionable
Beta
1.95

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:TCRR) was last updated on 9/23/2025 by MarketBeat.com Staff
From Our Partners